IQVIA Holdings, Inc. IQV
Price alert —
Sign in to get a one-time email the moment IQV crosses your price. Free accounts included.
Sign in / create a free accountPrice chart
Loading…
Latest bar · IQV
Momentum reads · latest daily barGreen means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.
Financial overlay · last 12 quarters
The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | $4.2B | $0.3B | $0.6B | $0.5B | 6.6% | 13.6% |
| 2025-12-31 | $4.4B | $0.5B | $0.7B | $0.6B | 11.8% | 14.9% |
| 2025-09-30 | $4.1B | $0.3B | $0.6B | $0.8B | 8.1% | 14.0% |
| 2025-06-30 | $4.0B | $0.3B | $0.5B | $0.3B | 6.6% | 13.4% |
| 2025-03-31 | $3.8B | $0.2B | $0.5B | $0.4B | 6.5% | 13.7% |
Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.
Compare IQV vs peers
Line IQV up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.
Add tickers to compare with IQV
~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.
Earnings replay · last 20 reports
How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.
| Date | EPS actual | EPS est | Surprise | Next-day |
|---|---|---|---|---|
| 2026-05-05 | 2.90 | 2.82 | +3.0% | +0.0% |
| 2026-02-05 | 3.42 | 3.40 | +0.7% | +3.6% |
| 2025-10-28 | 3.00 | 2.98 | +0.8% | -0.1% |
| 2025-07-22 | 2.81 | 2.77 | +1.4% | +3.7% |
| 2025-05-06 | 2.70 | 2.63 | +2.6% | +4.9% |
| 2025-02-06 | 3.12 | 3.11 | +0.4% | -0.9% |
| 2024-10-31 | 2.84 | 2.81 | +1.0% | +1.6% |
| 2024-07-22 | 2.64 | 2.56 | +3.0% | -2.6% |
| 2024-05-02 | 2.54 | 2.48 | +2.4% | +0.6% |
| 2024-02-14 | 2.84 | 2.82 | +0.7% | -0.8% |
| 2023-11-01 | 2.49 | 2.45 | +1.8% | +5.8% |
| 2023-08-01 | 2.43 | 2.37 | +2.5% | -0.0% |
| 2023-04-27 | 2.45 | 2.41 | +1.7% | +2.5% |
| 2023-02-10 | 2.78 | 2.76 | +0.6% | +4.2% |
| 2022-10-26 | 2.48 | 2.38 | +4.0% | -0.8% |
| 2022-07-21 | 2.44 | 2.38 | +2.4% | -1.7% |
| 2022-04-27 | 2.47 | 2.42 | +2.2% | +4.4% |
| 2022-02-15 | 2.55 | 2.43 | +4.8% | +1.6% |
| 2021-10-21 | 2.17 | 2.12 | +2.2% | +0.8% |
| 2021-07-27 | 2.13 | 2.08 | +2.5% | +0.9% |
Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.
Peer comparison · Healthcare
Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| IQV ★ | $34B | 25.7 | 14.6 | 2.1 | 16.2 | 5.5 | 33.0% | 8.4% | 15.0% | 6.61% |
| LLY | $1,051B | 41.8 | 26.3 | 14.6 | 30.1 | 33.8 | 82.8% | 55.5% | 169.9% | 0.87% |
| UNH | $387B | 32.1 | 19.2 | 0.9 | 17.7 | 4.0 | 19.5% | 0.4% | 61.5% | 5.88% |
| JNJ | $609B | 29.3 | 19.7 | 6.2 | 18.4 | 7.5 | 68.1% | 6.6% | -1.0% | — |
| MRK | $315B | 36.0 | 13.2 | 4.8 | 12.1 | 6.9 | 76.7% | 4.9% | — | 4.46% |
| ABBV | $450B | 124.8 | 15.6 | 7.2 | 17.2 | -67.6 | 72.0% | 12.4% | -46.2% | 4.63% |
| PFE | $143B | 19.1 | 8.8 | 2.3 | 7.6 | 1.6 | 74.8% | 5.4% | -10.1% | 8.67% |
| TMO | $198B | 29.2 | 19.5 | 4.4 | 21.1 | 3.8 | 40.9% | 6.2% | 11.3% | 2.79% |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.
Top institutional holders
Top-10 concentration: 45.36%
| Holder | Shares | % out |
|---|---|---|
| Blackrock Inc. | 15,027,444 | 9.00% |
| Harris Associates L.P. | 12,183,275 | 7.30% |
| Vanguard Capital Management LLC | 11,026,983 | 6.61% |
| Vanguard Portfolio Management LLC | 7,576,001 | 4.54% |
| State Street Corporation | 7,476,962 | 4.48% |
| JPMORGAN CHASE & CO | 5,407,690 | 3.24% |
| Artisan Partners Limited Partnership | 5,058,865 | 3.03% |
| Geode Capital Management, LLC | 4,463,052 | 2.67% |
| Boston Partners | 4,238,958 | 2.54% |
| Invesco Ltd. | 3,261,778 | 1.95% |
Insider activity · 90d
12 buys / 0 sells · ratio 12.0 · Finnhub
- Wims Morris Leslie BUY 6,636 @ $178.64
- Fasano Jim BUY 6,073 @ $178.64
- GOGGINS COLLEEN A BUY 5,114 @ $178.64
- DANHAKL JOHN G BUY 3,129 @ $178.64
- Stamps Sheila A BUY 4,210 @ $160.68
- Wims Morris Leslie BUY 6,465 @ $160.68
- Kaelin William G Jr BUY 1,571 @ $160.68
- LEONARD JOHN M BUY 16,946
- Fasano Jim BUY 5,845 @ $160.68
- Burt Carol BUY 7,533
Analyst estimates
FinnhubWhat Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.
SEC filings
The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.
No CIK found for IQV.
About IQV
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project m…
Options picks · IQV
ITM + OTM ideas from the latest scanLoading…
Congress trades · IQV
STOCK Act disclosuresLoading…
SEC filings & insiders · IQV
EDGAR · liveLoading…
Holders · IQV
Institutions & insider activityLoading…